Ok Ercan, Demirci Cenk, Asci Gulay, Yuksel Kivanc, Kircelli Fatih, Koc Serkan Kubilay, Erten Sinan, Mahsereci Erkan, Odabas Ali Rıza, Stuard Stefano, Maddux Franklin W, Raimann Jochen G, Kotanko Peter, Kerr Peter G, Chan Christopher T
Ege University, Izmir, Turkey.
Fresenius Medical Care, Izmir, Turkey.
Kidney Int Rep. 2023 Sep 15;8(12):2603-2615. doi: 10.1016/j.ekir.2023.09.007. eCollection 2023 Dec.
More frequent and/or longer hemodialysis (HD) has been associated with improvements in numerous clinical outcomes in patients on dialysis. Home HD (HHD), which allows more frequent and/or longer dialysis with lower cost and flexibility in treatment planning, is not widely used worldwide. Although, retrospective studies have indicated better survival with HHD, this issue remains controversial. In this multicenter study, we compared thrice-weekly extended HHD with in-center conventional HD (ICHD) in a large patient population with a long-term follow-up.
We matched 349 patients starting HHD between 2010 and 2014 with 1047 concurrent patients on ICHD by using propensity scores. Patients were followed-up with from their respective baseline until September 30, 2018. The primary outcome was overall survival. Secondary outcomes were technique survival; hospitalization; and changes in clinical, laboratory, and medication parameters.
The mean duration of dialysis session was 418 ± 54 minutes in HHD and 242 ± 10 minutes in patients on ICHD. All-cause mortality rate was 3.76 and 6.27 per 100 patient-years in the HHD and the ICHD groups, respectively. In the intention-to-treat analysis, HHD was associated with a 40% lower risk for all-cause mortality than ICHD (hazard ratio [HR] = 0.60; 95% confidence interval [CI] 0.45 to 0.80; < 0.001). In HHD, the 5-year technical survival was 86.5%. HHD treatment provided better phosphate and blood pressure (BP) control, improvements in nutrition and inflammation, and reduction in hospitalization days and medication requirement.
These results indicate that extended HHD is associated with higher survival and better outcomes compared to ICHD.
更频繁和/或更长时间的血液透析(HD)已与透析患者众多临床结局的改善相关。家庭血液透析(HHD)能以更低成本进行更频繁和/或更长时间的透析,并在治疗计划上具有灵活性,但在全球范围内并未得到广泛应用。尽管回顾性研究表明HHD患者生存率更高,但这个问题仍存在争议。在这项多中心研究中,我们在大量患者群体中对每周三次的延长HHD与中心常规血液透析(ICHD)进行了长期随访比较。
我们使用倾向评分将2010年至2014年间开始接受HHD的349例患者与1047例同时期接受ICHD的患者进行匹配。患者从各自的基线开始随访至2018年9月30日。主要结局是总生存率。次要结局是技术生存率、住院情况以及临床、实验室和用药参数的变化。
HHD组透析疗程的平均时长为418±54分钟,ICHD组患者为242±10分钟。HHD组和ICHD组的全因死亡率分别为每100患者年3.76例和6.27例。在意向性分析中,HHD与全因死亡率比ICHD低40%的风险相关(风险比[HR]=0.60;95%置信区间[CI]为0.45至0.80;P<0.001)。在HHD组中,5年技术生存率为86.5%。HHD治疗能更好地控制磷酸盐和血压(BP),改善营养和炎症状况,并减少住院天数和用药需求。
这些结果表明,与ICHD相比,延长HHD与更高的生存率和更好的结局相关。